Drugs / JNJ-26528398
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01520142 | Nov 2011 → Apr 2012 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-26528398 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01520142 ↗ |
| Route | Oral | “receive an oral solution of JNJ-26528398 3 mg once daily for 7 days” NCT01520142 ↗ |